Keymed Biosciences, Inc.

As of December 31, 2025, Keymed Biosciences, Inc. carries a market capitalization of 15.75B, placing it among publicly traded companies globally. Its enterprise value stands at 14.48B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Keymed Biosciences, Inc.'s next confirmed earnings release is scheduled for March 30, 2027.

As of December 31, 2025, Keymed Biosciences, Inc. has 294.60M shares outstanding.

These figures are as of December 31, 2025.

As of December 31, 2025, Keymed Biosciences, Inc. maintains a current ratio of 2.90, meaning it holds 2.9x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended December 31, 2025.

As of the close on October 23, 2026, Keymed Biosciences, Inc.'s stock has gained approximately 34.29% over the past 52 weeks. The 50-day moving average sits at 77.93, while the 200-day moving average is 68.30.

As of December 31, 2025, Keymed Biosciences, Inc. holds 2.14B in cash and equivalents against 877.56M in total debt, resulting in a net debt position of 293.86M. Total book value stands at 3.09B, with working capital of 1.77B providing operational flexibility.